Skip to main content
HCPCS J9381 · Level II · Part B drug

J9381: teplizumab-mzwv (Tzield), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9381

Billing unit
5 MCG
Inj teplizumab mzwv 5 mcg
ASP payment limit
$39.274
October 2026; +0.2% vs July 2026
Practitioner MUE
800
MAI 3
OPPS status
SI K
APC 9112
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9381 is the Level II code for Injection, teplizumab-mzwv, 5 mcg, billed per 5 MCG. The Medicare Part B ASP payment limit for October 2026 is $39.274 per billing unit, up 0.2% from July 2026. The practitioner MUE allows up to 800 units per date of service (MAI 3), so a full 800-unit day is $31,419.20 at the current limit. Under OPPS it carries status indicator K in APC 9112. J9381 is billed in units of 5 MCG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Tzield by Provention Bio, Inc. No current Billing and Coding Article lists J9381, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9381 at $39.274 per 5 MCG for October 2026, derived from manufacturer average sales price plus 6%, compared with $39.217 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9381
QuarterPayment limitPerCoinsurance
October 2026$39.2745 MCG20%
July 2026$39.2175 MCG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J9381. Report the NDC in the claim's drug segment and bill the number of J9381 units that equals the quantity administered divided by 5 MCG; the last column gives units per full package.

NDCs that crosswalk to J9381
NDCDrug nameLabelerPackage sizeBilling units / package
73650-0316-01TzieldProvention Bio, Inc.2 × 1400

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J9381. For practitioners the limit is 800 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9381 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services8003 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital8003 Date of Service Edit: ClinicalCMS Policy

MUE for J9381 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9381 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9381 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9381 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9381 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9381 carries status indicator K and is assigned to APC 9112, with a published national unadjusted payment of $39.274. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9381 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $39.27 per 5 MCG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9381 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9381

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9381

What does HCPCS code J9381 describe?

J9381 is defined by CMS as "Injection, teplizumab-mzwv, 5 mcg". Each billing unit represents 5 MCG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9381 a CPT code?

No. J9381 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as teplizumab-mzwv (Tzield); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9381 reports the drug itself in 5 mcg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9381 in October 2026?

The ASP-based payment limit is $39.274 per 5 MCG, with 20% beneficiary coinsurance. The July 2026 limit was $39.217. Commercial payers use their own fee schedules.

How many units of J9381 can be billed per day?

The practitioner Medically Unlikely Edit is 800 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J9381?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Tzield (Provention Bio, Inc.). For example NDC 73650-0316-01 (package size 2) equals 400 billing units of J9381.

Does J9381 have NCCI bundling edits?

No active practitioner PTP pairs list J9381 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.